- Sarepta reported encouraging early-stage clinical data indicating its experimental RNA-based therapies showed promise.
- Preliminary trial findings demonstrated dose-dependent increases in drug presence within muscle tissue.
- The company’s integrin-targeted siRNA delivery approach is designed to improve drug uptake into muscle cells.
Sarepta Therapeutics Inc. (SRPT) on Wednesday released initial results from two investigational programs targeting genetic muscle diseases, demonstrating encouraging safety and biological activity in early trials.
The findings suggest the company’s approach may overcome longstanding delivery challenges in RNA therapies.
Focus On Rare Muscle Disorders
The therapies, identified as SRP-1001 and SRP-1003, are being studied for facioscapulohumeral muscular dystrophy type 1 and myotonic dystrophy type 1, respectively.
These conditions stem from abnormal genetic activity that leads to harmful protein production or toxic RNA buildup, progressively damaging muscle tissue.
Following the update, Sarepta stock traded over 3% higher in Wednesday’s premarket. On Stocktwits, retail sentiment jumped to ‘extremely bullish’ from ‘neutral’ territory the previous day. Message volume shifted to ‘high’ from ‘low’ levels in 24 hours.
Early Clinical Data Shows Promise
Early-stage studies showed that both candidates exhibited increasing muscle exposure as doses increased. Researchers also observed reductions in disease-related molecular targets after a single administration.
“These preliminary clinical data show consistent dose-dependent increases in plasma and muscle drug exposures across clinical and nonclinical studies and suggest that the αvβ6 integrin-targeting ligand mediates robust siRNA muscle delivery, which we hypothesize will ultimately enable higher dosing and translate into clinical efficacy for patients with FSHD1 and DM1.”
-Louise Rodino-Klapac, President, Research & Development and Technical Operations, Sarepta Therapeutics
Sarepta’s approach relies on a targeted delivery system designed to improve how small interfering RNA (siRNA) treatments reach affected muscle cells. By using a specialized integrin-targeting mechanism, the therapy aims to enhance drug penetration.
SRPT stock has gained over 4% year-to-date.
Also See: Trump Taps Mark Zuckerberg, Larry Ellison, Jensen Huang For AI Advisory Council: Report
For updates and corrections, email newsroom[at]stocktwits[dot]com.